Ali Hydar
Department of Pathology, University of Pennsylvania School of Dental Medicine, 240 South 40 Street, Philadelphia, PA, 19104-6030.
J Immunobiol. 2016 Dec;1(4). Epub 2016 Dec 28.
Mast cells (MCs) are tissue resident immune cells that are best known for their roles in allergic and inflammatory diseases. In addition to the high affinity IgE receptor (FcεRI), MCs express numerous G protein coupled receptors (GPCRs), which are the most common targets of drug therapy. Neurokinin 1 receptor (NK-1R) is expressed on MCs and contributes to IgE and non-IgE-mediated responses in mice. Although NK-1R antagonists are highly effective in modulating experimental allergic and inflammatory responses in mice they lack efficacy in humans. This article reviews recent findings that demonstrate that while neuropeptides (NPs) activate murine MCs via NK-1R and Mas related G protein coupled receptor B2 (MrgprB2), they activate human MCs via Mas-related G protein coupled receptor X2 (MRGPRX2). Interestingly, conventional NK-1R antagonists have off-target activity against mouse MrgprB2 but not human MRGPRX2. These findings suggest that the failure to translate studies with NK-1R antagonists from mouse studies to the clinic likely reflects their lack of effect on human MRGPRX2. A unique feature of MRGPRX2 that distinguishes it from other GPCRs is that it is activated by a diverse group of ligands that include; neuropeptides, cysteine proteases, antimicrobial peptides and cationic proteins released from activated eosinophils. Thus, the development of small molecule MRGPRX2-specific antagonists or neutralizing antibodies may provide new targets for the treatment of MC-mediated allergic and inflammatory diseases.
肥大细胞(MCs)是驻留在组织中的免疫细胞,因其在过敏性和炎症性疾病中的作用而最为人所知。除了高亲和力IgE受体(FcεRI)外,肥大细胞还表达多种G蛋白偶联受体(GPCRs),这些受体是药物治疗最常见的靶点。神经激肽1受体(NK-1R)在肥大细胞上表达,并参与小鼠中IgE和非IgE介导的反应。尽管NK-1R拮抗剂在调节小鼠实验性过敏和炎症反应方面非常有效,但它们在人类中缺乏疗效。本文综述了最近的研究发现,即神经肽(NPs)通过NK-1R和Mas相关G蛋白偶联受体B2(MrgprB2)激活小鼠肥大细胞,而通过Mas相关G蛋白偶联受体X2(MRGPRX2)激活人类肥大细胞。有趣的是,传统的NK-1R拮抗剂对小鼠MrgprB2具有脱靶活性,但对人类MRGPRX2没有脱靶活性。这些发现表明,将NK-1R拮抗剂的研究从小鼠研究转化到临床失败,可能反映了它们对人类MRGPRX2缺乏作用。MRGPRX2与其他GPCRs的一个独特区别在于,它被多种配体激活,这些配体包括:神经肽、半胱氨酸蛋白酶、抗菌肽和从活化嗜酸性粒细胞释放的阳离子蛋白。因此,开发小分子MRGPRX2特异性拮抗剂或中和抗体可能为治疗肥大细胞介导的过敏性和炎症性疾病提供新的靶点。